Replies to post #114626 on Anavex Life Sciences Corp (AVXL)

[Gator328]

I don't think that a lack of news for an extended period of time suggests problems, especially in light of other ancillary developments.

You have to ask yourself why all these renowned MDs would join the SAB -- they've presumably seen the most recent data -- and while it's possible they are looking for a free handout, it's not like Anavex is flush with cash and paying them mid-six figures to join the board.

Usually compensation comes in the form of stock options. So again, why would they waste their time advising a company that has no prospects, and accept compensation that is soon to be worthless?

If the company were going down the tubes, why aren't we hearing about any resignations from the SAB?

The most recent addition to the advisory board is on the record stating there are three trials that will start in the near future -- if the data were terrible, why would Anavex move forward with P3 instead of trying to focus attention on one of its other compounds like 371, which by all accounts is even more powerful (even the brilliant Martin Shkreli admitted that 371 is the one that's going to work if any do in the AVXL pipeline, lol).

So yeah, I guess you can look at the lack of news as being a negative -- if you're impatient or a trader. But if you're in this for the long haul, the lack of news isn't all that big of a deal. It'll come eventually, and silence does not always mean bad data. Sometimes it means there's nothing to report, sometimes it means there are negotiations ongoing where it can't be reported, and sometimes it means that the company doesn't any any additional and unnecessary volatility while they're trying to raise funds.